BACKGROUND: Progressive multifocal leukoencephalopathy (PML) occurs in a fraction of patients with multiple sclerosis who were treated with natalizumab. Most adults who are infected with the JC virus, the etiologic agent in PML, do not have symptoms. We sought to determine whether exposure to natalizumab causes subclinical reactivation and neurotropic transformation of JC virus. METHODS: We followed 19 consecutive patients with multiple sclerosis who were treated with natalizumab over an 18-month period, performing quantitative polymerase-chain-reaction assays in blood and urine for JC virus reactivation; BK virus, a JC virus-related polyomavirus, was used as a control. We determined JC virus-specific T-cell responses by means of an enzyme-linked immunospot assay and antibody responses by means of an enzyme-linked immunosorbent assay and analyzed JC virus regulatory-region sequences. RESULTS: After 12 months of natalizumab therapy, the prevalence of JC virus in the urine of the 19 patients increased from a baseline value of 19% to 63% (P=0.02). After 18 months of treatment, JC virus was detectable in 3 of 15 available plasma samples (20%) and in 9 of 15 available samples of peripheral-blood mononuclear cells (60%) (P=0.02). JC virus regulatory-region sequences in blood samples and in most of the urine samples were similar to those usually found in PML. Conversely, BK virus remained stable in urine and was undetectable in blood. The JC virus-specific cellular immune response dropped significantly between 6 and 12 months of treatment, and variations in the cellular immune response over time tended to be greater in patients in whom JC viremia developed. None of the patients had clinical or radiologic signs of PML. CONCLUSIONS: Subclinical reactivation of JC virus occurs frequently in natalizumab-treated patients with multiple sclerosis. Viral shedding is associated with a transient drop in the JC virus-specific cellular immune response. 2009 Massachusetts Medical Society
BACKGROUND: Progressive multifocal leukoencephalopathy (PML) occurs in a fraction of patients with multiple sclerosis who were treated with natalizumab. Most adults who are infected with the JC virus, the etiologic agent in PML, do not have symptoms. We sought to determine whether exposure to natalizumab causes subclinical reactivation and neurotropic transformation of JC virus. METHODS: We followed 19 consecutive patients with multiple sclerosis who were treated with natalizumab over an 18-month period, performing quantitative polymerase-chain-reaction assays in blood and urine for JC virus reactivation; BK virus, a JC virus-related polyomavirus, was used as a control. We determined JC virus-specific T-cell responses by means of an enzyme-linked immunospot assay and antibody responses by means of an enzyme-linked immunosorbent assay and analyzed JC virus regulatory-region sequences. RESULTS: After 12 months of natalizumab therapy, the prevalence of JC virus in the urine of the 19 patients increased from a baseline value of 19% to 63% (P=0.02). After 18 months of treatment, JC virus was detectable in 3 of 15 available plasma samples (20%) and in 9 of 15 available samples of peripheral-blood mononuclear cells (60%) (P=0.02). JC virus regulatory-region sequences in blood samples and in most of the urine samples were similar to those usually found in PML. Conversely, BK virus remained stable in urine and was undetectable in blood. The JC virus-specific cellular immune response dropped significantly between 6 and 12 months of treatment, and variations in the cellular immune response over time tended to be greater in patients in whom JC viremia developed. None of the patients had clinical or radiologic signs of PML. CONCLUSIONS: Subclinical reactivation of JC virus occurs frequently in natalizumab-treated patients with multiple sclerosis. Viral shedding is associated with a transient drop in the JC virus-specific cellular immune response. 2009 Massachusetts Medical Society
Authors: Marco A Lima; Angela Marzocchetti; Patrick Autissier; Troy Tompkins; Yiping Chen; Jennifer Gordon; David B Clifford; Rajesh T Gandhi; Nagagopal Venna; Joseph R Berger; Igor J Koralnik Journal: J Virol Date: 2007-01-17 Impact factor: 5.103
Authors: Raphael P Viscidi; Dana E M Rollison; Emma Viscidi; Barbara Clayman; Elizabeth Rubalcaba; Richard Daniel; Eugene O Major; Keerti V Shah Journal: Clin Diagn Lab Immunol Date: 2003-03
Authors: Caroline Ryschkewitsch; Peter Jensen; Jean Hou; Gary Fahle; Steven Fischer; Eugene O Major Journal: J Virol Methods Date: 2004-11 Impact factor: 2.014
Authors: Jacques Gasnault; Mufide Kahraman; Marie Ghislaine de Goër de Herve; Deniz Durali; Jean-François Delfraissy; Yassine Taoufik Journal: AIDS Date: 2003-07-04 Impact factor: 4.177
Authors: Norman L Letvin; Srini S Rao; Vi Dang; Adam P Buzby; Birgit Korioth-Schmitz; Dilani Dombagoda; Jenny G Parvani; Ryon H Clarke; Liat Bar; Kevin R Carlson; Pamela A Kozlowski; Vanessa M Hirsch; John R Mascola; Gary J Nabel Journal: J Virol Date: 2007-08-08 Impact factor: 5.103
Authors: Renaud A Du Pasquier; Marcelo J Kuroda; Yue Zheng; Jims Jean-Jacques; Norman L Letvin; Igor J Koralnik Journal: Brain Date: 2004-06-23 Impact factor: 13.501
Authors: Renaud A Du Pasquier; Marcelo J Kuroda; Joern E Schmitz; Yue Zheng; Kristi Martin; Fred W Peyerl; Michelle Lifton; Darci Gorgone; Patrick Autissier; Norman L Letvin; Igor J Koralnik Journal: J Virol Date: 2003-11 Impact factor: 5.103
Authors: Martyn K White; Ilker K Sariyer; Jennifer Gordon; Serena Delbue; Valeria Pietropaolo; Joseph R Berger; Kamel Khalili Journal: Rev Med Virol Date: 2015-12-14 Impact factor: 6.989
Authors: Spyridon Chalkias; Xin Dang; Evelyn Bord; Marion C Stein; R Philip Kinkel; Jacob A Sloane; Maureen Donnelly; Carolina Ionete; Maria K Houtchens; Guy J Buckle; Stephanie Batson; Igor J Koralnik Journal: Ann Neurol Date: 2014-06-10 Impact factor: 10.422